Clinical Trial

A Study of HRS-2329 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is an open-label, multi-center phase I clinical study to evaluate the safety, tolerability, and pharmacokinetics of HRS-2329 in participants with advanced solid tumors harboring RAS mutations or amplifications.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-17.
Status change: Not Yet Recruiting → Recruiting 2026-03-05
Trial Details
NCT Number NCT07189949
Lead Sponsor Jiangsu HengRui Medicine Co., Ltd.
Conditions Advanced Solid Tumors Harboring RAS Mutations or Amplifications
Enrollment 120 participants
Start Date 2025-10-16
Primary Completion 2028-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-03-06